Dual-target antibacterial agents single molecules engaging two essential bacterial targets through intramolecular synergy are gaining traction as a strategy to counter AMR’s stalled pipeline
Dual-target antibacterial agents single molecules engaging two essential bacterial targets through intramolecular synergy are gaining traction as a strategy to counter AMR’s stalled pipeline: 90 agents in clinical development in 2025 (down from 97 in 2023), with only 5 active…